Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2025 07:00 ET | Source: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
March 08, 2022 08:27 ET | Source: BioNTech SE

BioNTech und Regeneron erweitern strategische Zusammenarbeit zur klinischen Entwicklung von FixVac und Libtayo® (Cemiplimab) Kombination gegen nicht-kleinzelliges Lungenkarzinom

BioNTech und Regeneron planen die gemeinsame Durchführung klinischer Studien zur Untersuchung des FixVac-Kandidaten BNT116 in Kombination mit Libtayo zur Behandlung von fortgeschrittenem...
March 08, 2022 08:27 ET | Source: BioNTech SE

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

BioNTech and Regeneron plan to jointly conduct clinical trials evaluating FixVac candidate BNT116 in combination with Libtayo for the treatment of advanced non-small cell lung cancer (NSCLC)The...
July 31, 2020 02:00 ET | Source: BioNTech SE

BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombinationstherapie aus FixVac und Libtayo® (Cemiplimab) bekannt

BioNTech und Regeneron planen die gemeinsame Durchführung einer randomisierten Phase-2-Studie mit einer Kombination aus FixVac BNT111 und Libtayo für die Behandlung von maligem Melanom (schwarzer...
July 31, 2020 02:00 ET | Source: BioNTech SE

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma

BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockadeCombines two...